Analyst Price Target is $16.50
▲ +71.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is $16.50, with a high forecast of $17.00 and a low forecast of $16.00. The average price target represents a 71.70% upside from the last price of $9.61.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Avadel Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded 1990 and is headquartered in Dublin, Ireland.